Author:
Kluberg Sheryl A.,Simon Andrew L.,Alam Sarah M.,Peters Alexander,Horgan Casie,Li Dongdong,Moyneur Erick,Messenger-Jones Elizabeth,Platt Richard,McMahill-Walraven Cheryl N.,Djibo Djeneba Audrey,Daniels Kimberly,Jamal-Allial Aziza,Pernar Claire H.,Ziyadeh Najat J.,Ma Qianli,Selvan Mano,Spence O'Mareen,Oraichi Driss,Seifert Harry,Franck Valentine,Gamble Susan,Yun Huifeng
Funder
GlaxoSmithKline Biologicals SA
Reference40 articles.
1. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines;Dooling;MMWR Morb Mortal Wkly Rep,2018
2. Herpes zoster: a brief definitive review;Cohen;Cornea,2021
3. U.S. Food and Drug Administration. Shringrix (zoster vaccine recombinant, adjuvanted), suspension for intramuscular injection. Highlights of Prescribing Information, https://www.fda.gov/media/108597/download?attachment; 2023 [accessed September 28, 2023].
4. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults;Lal;N Engl J Med,2015
5. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older;Cunningham;N Engl J Med,2016